Conference Proceedings
Outcomes of Stages I and II Follicular Lymphoma in the Era of 18F-FDG PET-CT Staging: An International Collaborative Study from the Australian Lymphoma Alliance
Joshua WD Tobin, Gabrielle Rule, Katherine Colvin, Lourdes Calvente, David C Hodgson, Chengetai Dunduru, Stephen Bell, James Gallo, Erica Tsang, Xuan Tan, Jessica Pearce, Jonathan Wong, Robert Campbell, Shao Yang Tneh, Sophie Shorten, Melissa Liet Hing Ng, Jacob Darch, Tara Cochrane, Constantine S Tam, Emad Uddin Abro Show all
BLOOD | AMER SOC HEMATOLOGY | Published : 2018
Abstract
Abstract Background Stage I/II or early-stage follicular lymphoma (ESFL) is considered potentially curable with radiotherapy (XRT). While XRT does achieve local disease control in >90% of cases, more than half the patients (pts) relapse by 10 years (yr), generally outside of the radiation field. A recent randomized controlled trial (TROG 99.03) demonstrated that combined modality therapy (CMT), with sequential XRT and systemic therapy, significantly improved PFS but not overall survival (OS) compared to XRT alone in ESFL. However, only half the pts were staged with 18F‐FDG positron emission tomography and computed tomography (PET) and 58% of CMT p..
View full abstract